Acceleron Pharma Sees Unusually High Options Volume (XLRN)

Acceleron Pharma Inc (NASDAQ:XLRN) was the recipient of some unusual options trading activity on Friday. Investors bought 508 call options on the company. This is an increase of approximately 916% compared to the average daily volume of 50 call options.

XLRN has been the topic of a number of research reports. Credit Suisse Group set a $51.00 target price on shares of Acceleron Pharma and gave the stock a “buy” rating in a research report on Tuesday, November 14th. HC Wainwright initiated coverage on shares of Acceleron Pharma in a research report on Thursday, October 12th. They set a “buy” rating and a $57.00 target price on the stock. Royal Bank of Canada reaffirmed a “hold” rating on shares of Acceleron Pharma in a research report on Thursday, November 2nd. Barclays raised their target price on shares of Acceleron Pharma from $42.00 to $50.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 20th. Finally, ValuEngine raised shares of Acceleron Pharma from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Two analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Acceleron Pharma presently has a consensus rating of “Buy” and an average target price of $44.56.

Shares of Acceleron Pharma (NASDAQ XLRN) opened at $42.78 on Wednesday. The firm has a market cap of $1,900.00, a P/E ratio of -16.58 and a beta of 1.59. Acceleron Pharma has a one year low of $23.07 and a one year high of $43.19.

Acceleron Pharma (NASDAQ:XLRN) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.67) by $0.02. The company had revenue of $3.00 million during the quarter, compared to the consensus estimate of $3.52 million. Acceleron Pharma had a negative net margin of 759.34% and a negative return on equity of 40.70%. Acceleron Pharma’s revenue was up .0% compared to the same quarter last year. During the same period last year, the firm earned ($0.55) earnings per share. research analysts forecast that Acceleron Pharma will post -2.65 EPS for the current fiscal year.

In related news, Director Jean George sold 105,122 shares of the stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $35.73, for a total value of $3,756,009.06. Following the sale, the director now directly owns 1,250 shares of the company’s stock, valued at approximately $44,662.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 3.90% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. GSA Capital Partners LLP acquired a new stake in shares of Acceleron Pharma during the third quarter worth $1,496,000. Iguana Healthcare Management LLC acquired a new stake in shares of Acceleron Pharma during the third quarter worth $2,612,000. Point72 Asset Management L.P. acquired a new stake in shares of Acceleron Pharma during the third quarter worth $2,721,000. Granahan Investment Management Inc. MA lifted its stake in shares of Acceleron Pharma by 15.2% during the third quarter. Granahan Investment Management Inc. MA now owns 217,091 shares of the biopharmaceutical company’s stock worth $8,102,000 after buying an additional 28,694 shares during the period. Finally, Perceptive Advisors LLC lifted its stake in shares of Acceleron Pharma by 127.2% during the third quarter. Perceptive Advisors LLC now owns 1,616,259 shares of the biopharmaceutical company’s stock worth $60,319,000 after buying an additional 905,000 shares during the period. Institutional investors own 85.70% of the company’s stock.

WARNING: This story was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.com-unik.info/2017/12/27/acceleron-pharma-sees-unusually-high-options-volume-xlrn.html.

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

What are top analysts saying about Acceleron Pharma? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Acceleron Pharma and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit